Your browser is no longer supported. Please, upgrade your browser.
Settings
PTI Proteostasis Therapeutics, Inc. daily Stock Chart
PTI [NASD]
Proteostasis Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.06 Insider Own17.86% Shs Outstand56.72M Perf Week-6.80%
Market Cap77.71M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float42.37M Perf Month2.24%
Income-54.60M PEG- EPS next Q-0.23 Inst Own22.40% Short Float5.98% Perf Quarter-12.74%
Sales0.00M P/S- EPS this Y28.00% Inst Trans1.62% Short Ratio2.24 Perf Half Y-18.93%
Book/sh0.86 P/B1.59 EPS next Y2.30% ROA- Target Price- Perf Year90.22%
Cash/sh0.86 P/C1.59 EPS next 5Y- ROE- 52W Range0.61 - 4.72 Perf YTD-39.91%
Dividend- P/FCF- EPS past 5Y5.70% ROI-98.00% 52W High-70.97% Beta1.16
Dividend %- Quick Ratio6.70 Sales past 5Y-0.60% Gross Margin- 52W Low124.59% ATR0.12
Employees42 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)44.70 Volatility11.86% 8.22%
OptionableYes Debt/Eq0.02 EPS Q/Q- Profit Margin- Rel Volume1.66 Prev Close1.49
ShortableYes LT Debt/Eq0.00 EarningsJun 09 AMC Payout- Avg Volume1.13M Price1.37
Recom2.00 SMA20-5.03% SMA50-4.40% SMA200-14.95% Volume1,882,133 Change-8.05%
Oct-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-12-17Reiterated Robert W. Baird Outperform $13 → $25
Apr-18-16Initiated Guggenheim Neutral
Mar-07-16Initiated Robert W. Baird Outperform $13
Mar-07-16Initiated RBC Capital Mkts Outperform $20
Mar-07-16Initiated Leerink Partners Outperform
Mar-07-16Initiated H.C. Wainwright Buy $15
Aug-06-20 08:20PM  
04:05PM  
Jun-05-20 04:05PM  
Jun-04-20 09:46AM  
Jun-01-20 07:00AM  
May-15-20 05:25PM  
04:10PM  
May-13-20 07:43AM  
May-12-20 09:02AM  
May-06-20 12:30PM  
Apr-24-20 09:29AM  
Apr-13-20 08:00AM  
Mar-10-20 04:36PM  
11:11AM  
Feb-26-20 09:56AM  
Feb-24-20 08:00AM  
Feb-21-20 10:12AM  
Feb-20-20 07:03AM  
Feb-19-20 11:19AM  
Feb-18-20 10:06AM  
Jan-22-20 07:00AM  
Jan-13-20 08:00AM  
Jan-09-20 12:16PM  
Jan-06-20 11:30AM  
Jan-03-20 09:56AM  
Dec-20-19 09:16AM  
Dec-17-19 09:07AM  
07:30AM  
Dec-16-19 02:01PM  
Dec-12-19 09:10AM  
Dec-11-19 07:00AM  
Dec-09-19 08:45AM  
Dec-03-19 07:00AM  
Dec-02-19 07:00AM  
Nov-29-19 12:15PM  
Nov-27-19 08:42AM  
Nov-14-19 01:31PM  
Nov-07-19 04:05PM  
Nov-06-19 07:00AM  
Nov-05-19 10:44AM  
Oct-29-19 10:33AM  
Oct-24-19 07:00AM  
Oct-21-19 07:00AM  
Oct-02-19 09:29AM  
Sep-26-19 07:00AM  
Sep-20-19 01:22PM  
Sep-19-19 04:05PM  
Aug-15-19 03:47PM  
Aug-07-19 06:05PM  
04:05PM  
10:30AM  
Aug-01-19 09:21AM  
Jul-25-19 07:00AM  
Jul-23-19 07:00AM  
Jul-15-19 11:19AM  
Jun-14-19 01:38PM  
Jun-04-19 07:00AM  
Jun-03-19 07:00AM  
May-31-19 08:25AM  
May-15-19 08:00AM  
May-13-19 08:00AM  
May-08-19 08:55PM  
07:47PM  
05:15PM  
May-07-19 10:47AM  
May-02-19 11:04AM  
May-01-19 10:32AM  
Apr-08-19 08:44AM  
Mar-26-19 12:11PM  
12:09PM  
07:36AM  
Mar-25-19 04:20PM  
12:35PM  
10:42AM  
07:00AM  
Mar-23-19 12:20PM  
Mar-07-19 08:40AM  
07:00AM  
Feb-27-19 08:00AM  
Feb-25-19 07:55AM  
Feb-20-19 07:00AM  
Feb-12-19 09:00AM  
Feb-07-19 10:54AM  
09:00AM  
Feb-06-19 12:15PM  
08:00AM  
Dec-21-18 12:25PM  
07:58AM  
Dec-20-18 04:30PM  
10:35AM  
Dec-19-18 08:50AM  
05:37AM  
Dec-17-18 02:09PM  
12:53PM  
09:54AM  
07:00AM  
Nov-28-18 08:41AM  
Nov-21-18 07:00AM  
Nov-19-18 08:39AM  
Nov-12-18 03:25PM  
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
New Enterprise Associates 12, 10% OwnerNov 27Sale2.521,166,7552,941,7394,270,691Nov 29 03:34 PM
New Enterprise Associates 12, 10% OwnerNov 26Sale2.45117,164287,1345,437,446Nov 29 03:34 PM
LQDA Liquidia Technologies, Inc. daily Stock Chart
LQDA [NASD]
Liquidia Technologies, Inc.
Index- P/E- EPS (ttm)-2.26 Insider Own0.50% Shs Outstand28.43M Perf Week12.48%
Market Cap229.52M Forward P/E- EPS next Y-1.80 Insider Trans- Shs Float18.76M Perf Month-16.40%
Income-48.60M PEG- EPS next Q-0.44 Inst Own37.20% Short Float9.95% Perf Quarter-8.26%
Sales8.10M P/S28.34 EPS this Y24.60% Inst Trans8.31% Short Ratio4.88 Perf Half Y2.98%
Book/sh0.77 P/B8.08 EPS next Y11.30% ROA-81.50% Target Price- Perf Year-14.91%
Cash/sh1.09 P/C5.72 EPS next 5Y- ROE-179.40% 52W Range2.65 - 12.10 Perf YTD45.50%
Dividend- P/FCF- EPS past 5Y- ROI-88.30% 52W High-48.60% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin90.00% 52W Low134.72% ATR0.50
Employees64 Current Ratio2.60 Sales Q/Q- Oper. Margin- RSI (14)47.28 Volatility6.38% 7.58%
OptionableYes Debt/Eq0.76 EPS Q/Q39.40% Profit Margin- Rel Volume0.68 Prev Close6.08
ShortableYes LT Debt/Eq0.43 EarningsAug 10 AMC Payout- Avg Volume382.78K Price6.22
Recom1.70 SMA200.35% SMA50-21.03% SMA2007.94% Volume261,127 Change2.30%
Nov-08-18Resumed Jefferies Buy
Sep-05-18Initiated Wedbush Outperform $26
Aug-20-18Initiated Needham Buy $30
Aug-20-18Initiated Jefferies Buy $22
Aug-05-20 05:30PM  
07:15AM  
Aug-03-20 09:20AM  
Jul-24-20 09:08AM  
Jul-08-20 10:35PM  
Jul-02-20 04:01PM  
Jun-30-20 07:41AM  
Jun-29-20 10:45PM  
10:30PM  
04:05PM  
04:01PM  
Jun-16-20 08:20AM  
Jun-12-20 07:09PM  
Jun-05-20 03:30PM  
May-29-20 10:31AM  
May-27-20 08:04PM  
May-22-20 10:01AM  
May-18-20 07:15AM  
May-11-20 04:01PM  
May-07-20 09:30AM  
May-06-20 06:30PM  
Apr-30-20 07:30AM  
Apr-09-20 07:30AM  
Apr-08-20 07:45AM  
Mar-11-20 08:15AM  
07:00AM  
Mar-04-20 12:30PM  
Feb-26-20 04:30PM  
04:30PM  
Jan-27-20 02:55PM  
08:00AM  
Jan-24-20 09:00AM  
Jan-15-20 07:29AM  
Dec-26-19 02:55PM  
10:32AM  
Dec-24-19 08:30AM  
Dec-20-19 06:21PM  
Nov-13-19 08:15AM  
07:00AM  
06:00AM  
Nov-06-19 08:00AM  
Nov-01-19 08:00AM  
Oct-23-19 10:33AM  
Oct-22-19 10:52AM  
Sep-25-19 04:05PM  
Sep-12-19 04:05PM  
Sep-03-19 07:00AM  
Aug-27-19 02:44PM  
Aug-08-19 04:05PM  
07:00AM  
Aug-02-19 09:00AM  
Jul-24-19 01:01PM  
Jun-28-19 08:35PM  
02:17PM  
Jun-26-19 04:15PM  
Jun-05-19 04:05PM  
Jun-03-19 08:30AM  
May-22-19 04:30PM  
May-14-19 04:15PM  
May-02-19 07:00AM  
Apr-23-19 04:05PM  
Apr-03-19 04:30PM  
Apr-02-19 08:00AM  
Mar-25-19 10:54AM  
Mar-21-19 07:56AM  
Mar-19-19 08:57AM  
Mar-18-19 04:45PM  
Mar-11-19 07:00AM  
Feb-26-19 07:00AM  
Feb-13-19 04:30PM  
Jan-07-19 07:00AM  
Dec-27-18 09:23AM  
Nov-27-18 04:45PM  
02:04PM  
Nov-14-18 04:30PM  
08:00AM  
07:55AM  
Nov-09-18 08:00AM  
Nov-01-18 08:14AM  
Oct-31-18 07:00AM  
Oct-23-18 08:00AM  
Sep-24-18 08:00AM  
Aug-20-18 03:45PM  
Aug-09-18 08:00AM  
Jul-31-18 02:45PM  
Jul-30-18 04:15PM  
Jul-25-18 07:02PM  
Jul-21-18 09:03AM  
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of novel products which utilize PRINT technology to transform the lives of patients. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreement with the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eshelman Ventures, LLC10% OwnerJul 02Buy8.001,875,00015,000,0007,034,744Jul 02 07:31 PM
Maynor BenjaminSVP, Research and DevelopmentMay 27Option Exercise2.694,75412,78811,735May 28 04:30 PM
Maynor BenjaminSVP, Research and DevelopmentApr 14Option Exercise1.856,13211,34410,300Apr 16 04:30 PM
Eshelman Ventures, LLC10% OwnerApr 06Buy5.2844,250233,715175,573Apr 07 05:18 PM
Eshelman Ventures, LLC10% OwnerApr 03Buy4.8535,000169,740131,323Apr 07 05:18 PM
Eshelman Ventures, LLC10% OwnerApr 02Buy4.967,22335,79296,323Apr 03 05:40 PM
Eshelman Ventures, LLC10% OwnerApr 01Buy4.8945,000220,12289,100Apr 03 05:40 PM
Eshelman Ventures, LLC10% OwnerMar 31Buy4.8730,000146,11244,100Apr 01 05:35 PM
Eshelman Ventures, LLC10% OwnerMar 30Buy4.7614,10067,10614,100Apr 01 05:35 PM
Canaan VIII LP10% OwnerDec 27Buy3.13319,488999,9972,917,169Jan 10 04:20 PM